

■ **BERICHTE + ANALYSEN + MEINUNGEN**

Individuelle Dosisanpassung: ein erklärtes Ziel der personalisierten Medizin

Pharmakokinetische Dosis- anpassung und Therapeutisches Drug Monitoring in der Praxis

Achim Fritsch, Klinische Pharmazie – Pharmazeutisches Institut, Universität Bonn

Literatur

- [1] Gesundheitsberichterstattung des Bundes. Niereninsuffizienz. Verfügbar unter: <http://www.gbe-bund.de/stichworte/Niereninsuffizienz.html> (letzter Zugriff: 03.2016).
- [2] The LK, Bertilsson L. Pharmacogenomics of CYP2D6: Molecular Genetics, Interethnic Differences and Clinical Importance. *Drug Metab Pharmacokinet* 2012; 27(1):55-67.
- [3] Jaehde U, Radziwill R, Kloft C. *Klinische Pharmazie: Grundlagen und Anwendungen*. 3. Auflage. Deutscher Apotheker Verlag, 2010.
- [4] Burton ME, Shaw LM, Schentag JJ, Evans WE. *Applied Pharmacokinetics & Pharmacodynamics*. 4. Auflage. Lippincott Williams & Wilkins; 2006.
- [5] Touw et al. Cost-Effectiveness of Therapeutic Drug Monitoring. *Ther Drug Monit* 2005; 27:10-17.
- [6] Henningsson A. et al. Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. *Eur J Cancer* 2003; 39(8):1105-1114.
- [7] Ette EI, Williams PJ. *Pharmacometrics – The Science of Quantitative Pharmacology*. 1. Auflage. John Wiley & Sons, 2007.
- [8] Friberg et al. Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs. *J Clin Oncol* 2002; 20(24):4713-4721.
- [9] Peters SA. *Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations*. 1. Auflage. John Wiley & Sons, 2012.
- [10] Excel®-Solver. Define and solve a problem by using Solver. Verfügbar unter: <https://support.office.com/en-us/article/Define-and-solve-a-problem-by-using-Solver-bdd10118-4133-4d09-b5fa-8a2841a33b10?rs=en-US&ui=en-US&ad=US> (letzter Zugriff: 03.2016).
- [11] Mould DR, Upton RN. Basic Concepts in Population Modeling, Simulation and Model based Drug Development. *CPT Pharmacometrics Syst Pharmacol* 2012; 1:e6.

- [12] Fuchs et al. Benchmarking Therapeutic Drug Monitoring Software: A Review of available Computer Tools. Clin Pharmacokinet 2013; 52:9-22.
- [13] Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol 2001; 52:5-10.
- [14] Patsalos PN et al. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49(7):1239 -1276.
- [15] BestDose®. Verfügbar unter: <http://www.lapk.org/bestdose.php> (letzter Zugriff: 03.2016).
- [16] MwPharm++®. Verfügbar unter: <http://mediware.cz/> (letzter Zugriff: 03.2016).
- [17] AWMF-Leitlinie: Strategien zur Sicherung rationaler Antibiotika Anwendung im Krankenhaus (S3). Stand: 12.2013. Verfügbar unter: <http://leitlinien.net> (letzter Zugriff: 03.2016).
- [18] Fachinformation Gentamicin B. Braun Infusionslösung, Stand: 02.2015. Verfügbar unter: <http://www.fachinfo.de> (letzter Zugriff: 03.2016)
- [19] Fachinformation Amikacin B. Braun Infusionslösung, Stand: 04.2014. Verfügbar unter: <http://www.fachinfo.de> (letzter Zugriff: 03.2016).
- [20] Freeman et al. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997; 39:677-686.
- [21] Roberts JA, Norris R, Paterson DL, Martin JH. Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol 2011; 73 (1):27-36.
- [22] Rybak MJ. The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin. CID 2006; 42 (Suppl 1):35-39.
- [23] Rudek MA, Chau CH, Figg W, McLeod HL. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. 2. Auflage. Springer 2014.
- [24] Gao B. et al. Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies. J Clin Oncol 2012; 30:4017-4025.
- [25] Paci A et al. Review of therapeutic drug monitoring of anticancer drugs part 1 – Cytotoxics. Eur J Cancer 2014; 50:2010-2019.
- [26] Alnaim L. Therapeutic drug monitoring of cancer chemotherapy. J Oncol Pharm Practice 2007; 13:207-221.
- [27] Calvert AH et al. Carboplatin Dosage: Prospective Evaluation of a Simple Formula Based on Renal Function. J Clin Oncol 1989; 7:1748-1756.
- [28] Engelhardt M, Berger DP, Duyster J, Mertelsmann R. Das Blaue Buch. 5. Auflage. Springer 2014.
- [29] Saif MW, Choma A, Salamone SJ, Chu E. Pharmacokinetically Guided Dose Adjustment of 5-Fluorouracil: A Rational Approach to improving Therapy Outcomes. J Natl Cancer Inst 2009; 101:1543-1552.

[30] Joerger et al. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: A study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group. Clin Cancer Res 2007; 51:618.

[31] Miller et al. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and leukemia group B study 9763. Clin Cancer Res 2004; 10(24):8325-8331.

[32] Joerger et al. Randomized study of individualized, pharmacokinetically-guided dosing of paclitaxel combined with carboplatin in advanced non-small cell lung cancer patients. Oncol Res Treat 2015; 38(suppl 5):14.

[33] Kraff et al. Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of Paclitaxel. Ther Drug Monit 2015; 37:725-732.

[34] IMS Institute. Development in Cancer Treatments, Market Dynamics Patient Access and Value: Global Oncology Trend Report 2015. Verfügbar unter: <http://www.imshealth.com/en/thought-leadership/ims-institute/reports/global-oncology-trend-2015> (letzter Zugriff: 03.2016).

[35] Widmer et al. Review of therapeutic drug monitoring of anticancer drugs part 2 – Targeted therapies. Eur J Cancer 2014; 50:2020-2036.

[36] Leitlinie: European Association of Urology: Guidelines on Renal Cell Carcinoma. Stand: 04.2014. Verfügbar unter: <https://uroweb.org/guideline/renal-cell-carcinoma/> (letzter Zugriff: 03.2016).

[37] Terada T, Noda S, Inui KI. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. Pharmacol Ther 2015; 152:125-134.

[38] Houk BE, Bello CL, Kang D. A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients. Clin Cancer Res 2009; 15:2497-2506.

[39] de Wit et al. Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study. Ther Drug Monit 2015; 37(3):331-338.

[40] ClinicalTrials.gov. Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma (SUP-R). Verfügbar unter: <https://www.clinicaltrials.gov/ct2/show/NCT02555748> (letzter Zugriff: 03.2016).

ENDE